Skip to main content
SpringerLink
Log in

Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma

  • Original Article
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

It is uncertain whether the tumor burden as assessed using FDG-PET has prognostic significance in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The authors undertook this study to determine whether a parameter that reflects both FDG uptake magnitude and the greatest tumor diameter is a prognostic indicator in DLBCL.

Materials and Methods

Forty-two DLBCL patients (age, 57.4 ± 15.5 years; male/female = 25/17; stage I/II/III/IV=5/17/10/10) who underwent FDG-PET before chemotherapy were enrolled. A lesion with the highest maximum standardized uptake value (MaxSUV) on the PET image was selected, and size-incorporated MaxSUV (SIMaxSUV) of mass was calculated as MaxSUV × greatest diameter (mm) on the transaxial PET image. Median follow-up duration was 20.0 months.

Results

Twelve (28.6% = 12/42) patients experienced disease progression, and 10 (23.8% = 10/42) died during follow-up. Among six variables [Ann Arbor stage, %Ki-67 expression, International Prognostic Index (IPI), MaxSUV, greatest diameter, and SIMaxSUV] investigated, only SIMaxSUV was found to be a single determinant of progression-free and overall survivals by multivariate analyses (p < 0.05).

Conclusion

These results suggest that SIMaxSUV, a new FDG-PET parameter that incorporates FDG uptake magnitude and the greatest tumor diameter, may be a useful indicator of prognosis in untreated DLBCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jhanwar YS, Straus DJ (2006) The role of PET in lymphoma. J Nucl Med 47:1326–1334

    PubMed  Google Scholar 

  2. Lossos IS, Morgensztern D (2006) Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 24:995–1007

    Article  CAS  PubMed  Google Scholar 

  3. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994

    Article  Google Scholar 

  4. Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN (2000) 18F-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma—comparison with CT. Leuk Lymphoma 39:543–553

    CAS  PubMed  Google Scholar 

  5. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P et al (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419

    CAS  PubMed  Google Scholar 

  6. Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J et al (2001) Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272–278

    Article  CAS  PubMed  Google Scholar 

  7. Schot B, van Imhoff G, Pruim J, Sluiter W, Vaalburg W, Vellenga E (2003) Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Br J Haematol 123:282–287

    Article  PubMed  Google Scholar 

  8. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J et al (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33:325–329

    CAS  PubMed  Google Scholar 

  9. Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Soderstrom KO et al (1995) Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86:3522–3527

    CAS  PubMed  Google Scholar 

  10. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B (1995) Predicting malignancy grade with PET in non-Hodgkin’s lymphoma. J Nucl Med 36:1790–1796

    CAS  PubMed  Google Scholar 

  11. Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE et al (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 23:4643–4651

    Article  PubMed  Google Scholar 

  12. Israel O, Keidar Z, Bar-Shalom R (2004) Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med 34:166–179

    Article  PubMed  Google Scholar 

  13. Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensuu H (1991) Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: a PET study. J Nucl Med 32:1211–1218

    CAS  PubMed  Google Scholar 

  14. Mackintosh JF, Cowan RA, Jones M, Harris M, Deakin DP, Crowther D (1988) Prognostic factors in stage I and II high and intermediate grade non-Hodgkin’s lymphoma. Eur J Cancer Clin Oncol 24:1617–1622

    Article  CAS  PubMed  Google Scholar 

  15. Oguchi M, Ikeda H, Isobe K, Hirota S, Hasegawa M, Nakamura K et al (2000) Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin’s lymphoma: a survey of the Japan lymphoma radiation therapy group. Int J Radiat Oncol Biol Phys 48:161–168

    Article  CAS  PubMed  Google Scholar 

  16. Wilder RB, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas F et al (2001) Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 91:2440–2446

    Article  CAS  PubMed  Google Scholar 

  17. Coiffier B (1999) How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin’s lymphoma patients? Ann Oncol 10:1141–1143

    Article  CAS  PubMed  Google Scholar 

  18. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K et al (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376–1381

    Article  CAS  PubMed  Google Scholar 

  19. Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16:1514–1523

    Article  CAS  PubMed  Google Scholar 

  20. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S et al (2004) Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 22:3255–3260

    Article  PubMed  Google Scholar 

  21. Leboulleux S, Dromain C, Bonniaud G, Auperin A, Caillou B, Lumbroso J et al (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91:920–925

    Article  CAS  PubMed  Google Scholar 

  22. Pryma DA, Schoder H, Gonen M, Robbins RJ, Larson SM, Yeung HW (2006) Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med 47:1260–1266

    PubMed  Google Scholar 

  23. Nguyen XC, Lee WW, Chung JH, Park SY, Sung SW, Kim YK et al (2007) FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol 62:214–219

    Article  PubMed  Google Scholar 

  24. Song YS, Lee WW, Chung J-H, Park SY, Kim YK, Kim SE (2007) Tumor burden assessed by maxSUV and metabolic size on FDG-PET predicts prognosis of small cell lung cancer. J Nucl Med [abstract]

  25. Cazaentre T, Morschhauser F, Vermandel M, Betrouni N, Prangere T, Steinling M et al (2009) Pre-therapy (18)F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-009-1275-x

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Xuan Canh Nguyen

    Present address: Department of Nuclear Medicine, Cho Ray Hospital, Ho Chi Minh City, Viet Nam

  2. Amr Mohamed Amin

    Present address: Department of Nuclear Medicine Diagnosis and Therapy, Cairo University, Cairo, Egypt

Authors and Affiliations

  1. Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 166 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707, Korea

    Xuan Canh Nguyen, Won Woo Lee, Amr Mohamed Amin, Jae Seon Eo & Sang Eun Kim

  2. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea

    Soo-Mee Bang & Jong Seok Lee

  3. Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, Korea

    Won Woo Lee & Sang Eun Kim

Authors
  1. Xuan Canh Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Won Woo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amr Mohamed Amin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jae Seon Eo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soo-Mee Bang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jong Seok Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sang Eun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Won Woo Lee.

Additional information

This work was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD, Basic Research Promotion Fund; KRF-2007-331-E00168).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nguyen, X.C., Lee, W.W., Amin, A.M. et al. Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma. Nucl Med Mol Imaging 44, 39–44 (2010). https://doi.org/10.1007/s13139-009-0009-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-009-0009-0

Keywords

Search

Navigation